Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 474645-27-7 Chemical Structure| 474645-27-7

Structure of Monomethyl auristatin E
CAS No.: 474645-27-7

Chemical Structure| 474645-27-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 that functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat various cancers.

Synonyms: MMAE; Vedotin; Brentuximab vedotin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Monomethyl auristatin E

CAS No. :474645-27-7
Formula : C39H67N5O7
M.W : 717.98
SMILES Code : O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@@H](NC)C(C)C)=O)=O)=O)OC)=O
Synonyms :
MMAE; Vedotin; Brentuximab vedotin
MDL No. :MFCD22124498

Safety of Monomethyl auristatin E

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H311-H331
Precautionary Statements:P261-P264-P270-P271-P280-P302+P352-P304+P340-P310-P330-P361-P403+P233-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Monomethyl auristatin E

cytoskeleton

Isoform Comparison

Biological Activity

Description
Monomethyl auristatin E (MMAE) produced under Good Manufacturing Practice (GMP) guidelines is a version of MMAE that inhibits tubulin polymerization[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
5637 cells 0.000001 to 100 ng/mL 72 hours To evaluate the antitumor activity of μMAE on 5637 cells, results showed that μMAE had strong antitumor activity against 5637 cells with high HER2 expression. PMC10646285
T24 cells 0.000001 to 100 ng/mL 72 hours To evaluate the antitumor activity of μMAE on T24 cells, results showed that μMAE had strong antitumor activity against T24 cells with moderate HER2 expression. PMC10646285
UM-UC-3 cells 0.000001 to 100 ng/mL 72 hours To evaluate the antitumor activity of μMAE on UM-UC-3 cells, results showed that μMAE had strong antitumor activity against UM-UC-3 cells with low HER2 expression. PMC10646285
TBP3743 cancer cells 10 μM 72 hours Evaluate the effect of RABiT-μMAE on the proliferation/cytotoxicity of TBP3743 cancer cells, results showed that RABiT-μMAE combined with radiotherapy significantly increased cytotoxicity PMC11273447
MC38 cancer cells 10 μM 72 hours Evaluate the effect of RABiT-μMAE on the proliferation/cytotoxicity of MC38 cancer cells, results showed that RABiT-μMAE combined with radiotherapy significantly increased cytotoxicity PMC11273447
HCT-116 5 nM 24 hours μMAE caused HCT-116 cells to accumulate in G2/M phase and increased radiation-induced DNA double-strand breaks PMC4458508
PANC-1 2 nM 24 hours μMAE caused PANC-1 cells to accumulate in G2/M phase and increased radiation-induced DNA double-strand breaks PMC4458508
779E 5.6 nM 72 hours μMAE showed cytotoxicity against 779E cells with an IC50 of 5.6 nM PMC4458508
PSMA-positive PC3pip cells 5 nM 24 hours To test the cytotoxicity of PSMA-1-μMAE-IR700 with light irradiation, the results showed that PSMA-1-μMAE-IR700 significantly enhanced cytotoxicity to PC3pip cells under light, indicating a synergistic effect of PDT and μMAE. PMC8899574
PSMA-negative PC3flu cells 5 nM 24 hours To test the cytotoxicity of PSMA-1-μMAE-IR700 with light irradiation, the results showed no significant cytotoxicity to PC3flu cells, indicating that the cell-killing effect is selective to PSMA expression. PMC8899574
THP-1 0.28±0.08 nM 5 days Anti-SCUBE1 antibody-drug conjugate significantly reduced the viability of MLL-r leukemia cells PMC10153537
NOMO-1 0.46±0.1 nM 5 days Anti-SCUBE1 antibody-drug conjugate significantly reduced the viability of MLL-r leukemia cells PMC10153537
MyLa cells 8.2 ng/mL 4-5 days To evaluate the killing effect of anti-ICOS-μMAE ADCs on MyLa cells, the results showed that the IC50 value of anti-ICOS-μMAE ADCs in MyLa cells was 8.2 ng/mL PMC7594390
MJ cells 30.6 ng/mL 4-5 days To evaluate the killing effect of anti-ICOS-μMAE ADCs on MJ cells, the results showed that the IC50 value of anti-ICOS-μMAE ADCs in MJ cells was 30.6 ng/mL PMC7594390
human gastric cancer cell line MKN-45 38.14 nM 72 hours Evaluate the killing activity of B9-μMAE against MKN-45 cells, results showed IC50 value of 38.14 nM PMC10834580
human pancreatic carcinoma cell line BxPC-3 25.60 nM 72 hours Evaluate the killing activity of B9-μMAE against BxPC-3 cells, results showed IC50 value of 25.60 nM PMC10834580
human colorectal cancer cell line LS174T 101.4 nM 72 hours Evaluate the killing activity of B9-μMAE against LS174T cells, results showed IC50 value of 101.4 nM PMC10834580
DX3puroβ6 (+) cells 0.058 ± 0.003 nM 48 hours To evaluate the cytotoxicity of [natCu]PDC-1 on cells expressing integrin αvβ6, results showed high cytotoxicity of [natCu]PDC-1 on DX3puroβ6 (+) cells. PMC10388305
BxPC-3 (+) cells 65.1 ± 10.6 nM 48 hours To evaluate the cytotoxicity of [natCu]PDC-1 on pancreatic cancer cells, results showed moderate cytotoxicity of [natCu]PDC-1 on BxPC-3 (+) cells. PMC10388305
MIAPaCa-2 (−) cells ≥250 nM 48 hours To evaluate the cytotoxicity of [natCu]PDC-1 on pancreatic cancer cells with low integrin αvβ6 expression, results showed low cytotoxicity of [natCu]PDC-1 on MIAPaCa-2 (−) cells. PMC10388305

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice HCT-116, KM12, HT29 colon cancer, OVCAR3 ovarian cancer, and MDA-MB-231 breast cancer xenograft models Intravenous injection 100 mg/kg/day (GDC0941), 0.3 mg/kg twice weekly (VCR) daily (GDC0941), twice weekly (VCR), until mice developed progressive disease To test the anti-tumor efficacy of m276-MMAE in vivo, results showed dose-dependent anti-tumor activity against multiple CD276-positive tumor xenograft models, with complete regression of many tumors at doses as low as 3 mg/kg. PMC5458750
BALB/c nude mice orthotopic bladder cancer model intravesical instillation 25 mg/kg/d Once daily for 4 weeks To evaluate the antitumor activity of MMAE in the orthotopic bladder cancer model, results showed that MMAE had some inhibitory effect on tumor growth, but the effect was not as significant as RC48-ADC. PMC10646285
Mice TBP3743 anaplastic thyroid cancer model Intravenous injection 5 mg/kg daily from PN10 to PN20 Evaluate the effect of RABiT-MMAE combined with radiotherapy on tumor growth inhibition, results showed that RABiT-MMAE combined with radiotherapy significantly inhibited tumor growth with no apparent toxicity PMC11273447
mice PANC-1 and HCT-116 tumor xenograft models intravenous injection 13.9 μmol/kg 4 consecutive days ACPP-cRGD-MMAE combined with radiation significantly prolonged tumor regression in xenograft models PMC4458508
Balb/c nude mice PC3pip tumor model Tail vein injection 3 days To evaluate the antitumor activity of PSMA-1-MMAE-IR700 with light irradiation, the results showed that PSMA-1-MMAE-IR700 significantly inhibited PC3pip tumor growth and prolonged survival time, indicating a synergistic antitumor effect of PDT and MMAE. PMC8899574
Mice MyLa cell xenograft model Intravenous injection 6 nmoles/day once daily for 2 days To evaluate the antitumor effect of anti-ICOS-MMAE ADCs in the MyLa cell xenograft model, the results showed that anti-ICOS-MMAE ADCs significantly prolonged the survival of mice and prevented metastasis PMC7594390
BALB/c nude mice BxPC-3 and MKN-45 xenograft models intravenous injection 100 nmol/kg Every 4 days, 5 times in total Evaluate the antitumor efficacy of B9-MMAE in BxPC-3 and MKN-45 xenograft models, results showed significant inhibition of tumor growth PMC10834580
mice DX3puroβ6 (+) and DX3puro (−) tumor-bearing mice intravenously (i.v.) 5 mg/kg Single dose, continued until the end of the experiment To evaluate the therapeutic efficacy of [natCu]PDC-1 on tumors expressing integrin αvβ6, results showed that [natCu]PDC-1 significantly prolonged the survival of DX3puroβ6 (+) tumor-bearing mice (median survival: 77 days) and suppressed tumor growth. PMC10388305

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02227199 Recurrent Adult Hodgkin Lympho... More >>ma Refractory Hodgkin Lymphoma TNFRSF8 Positive Less << Phase 1 Phase 2 Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Ajay K. Gopal    206-606-2037    agopal@u.washington.edu    Principal Investigator: Ajay K. Gopal Less <<
NCT00866047 - Completed - -
NCT02001623 Ovary Cancer ... More >>Cervix Cancer Endometrium Cancer Bladder Cancer Prostate Cancer (CRPC) Esophagus Cancer Lung Cancer(NSCLC) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Less << Phase 1 Phase 2 Active, not recruiting December 2018 -
NCT02623920 Diffuse Large B Cell Lymphoma ... More >> Mediastinal Large B-cell Lymphoma Grey Zone Lymphoma High Grade B Cell Lymphoma Follicular Lymphoma Marginal Zone Lymphoma Small Lymphocytic Lymphoma Less << Phase 2 Withdrawn(Pharmaceutical compa... More >>ny supplying the drug withdraw financial support. PI has decided to close study prior to enrollment of any patients.) Less << - United States, Arizona ... More >> Arizona Cancer Center at UMC North Tucson, Arizona, United States, 85724 Less <<
NCT02594163 Diffuse Large B-cell Lymphoma ... More >>Refractory Follicular B-cell Non-Hodgkin's Lymphoma Less << Phase 2 Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less << - -
NCT02594163 - Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less << - -
NCT03474107 Ureteral Cancer ... More >> Urothelial Cancer Bladder Cancer Less << Phase 3 Recruiting September 2021 -
NCT03274492 Diffuse Large B-Cell Lymphoma Phase 3 Recruiting April 15, 2023 -
NCT02139592 - Completed - Japan ... More >> Osaka, Japan Less <<
NCT00866047 Lymphoma, Large-Cell, Anaplast... More >>ic Lymphoma, Non-Hodgkin Less << Phase 2 Completed - -
NCT02191930 Hodgkin Lymphoma Phase 2 Recruiting April 2019 Germany ... More >> 1st Dept. of Medicine, Cologne University Hospital Recruiting Cologne, Germany, 50924 Contact: Michael Fuchs       ghsg@uk-koeln.de Less <<
NCT03264131 Lymphoma Adul... More >>t T-Cell Leukemia/Lymphoma Lymphatic Diseases Less << Phase 2 Recruiting January 30, 2026 United States, North Carolina ... More >> Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Bob Broomer    919-966-9257    bob_broomer@med.unc.edu Less <<
NCT03652441 Classical Hodgkin Lymphoma Phase 2 Not yet recruiting December 2022 Germany ... More >> 1st Department of Medicine, Cologne University Hospital Cologne, Germany Less <<
NCT03356054 DLBCL Phase 1 Phase 2 Not yet recruiting June 2025 Belgium ... More >> ZNA Not yet recruiting Antwerp, Belgium Netherlands AMC Not yet recruiting Amsterdam, Netherlands VUmc Not yet recruiting Amsterdam, Netherlands Haga hospital Not yet recruiting Den Haag, Netherlands UMCG Not yet recruiting Groningen, Netherlands MUMC Not yet recruiting Maastricht, Netherlands Antonius hospital Not yet recruiting Nieuwegein, Netherlands Radboudumc Not yet recruiting Nijmegen, Netherlands Erasmus MC Not yet recruiting Rotterdam, Netherlands UMCU Not yet recruiting Utrecht, Netherlands Isala Not yet recruiting Zwolle, Netherlands Spain Hospital Clinic de Barcelona Not yet recruiting Barcelona, Spain Institute Català d'Oncologica - Hospital Not yet recruiting Barcelona, Spain Hospital 12 de Octubre Not yet recruiting Madrid, Spain Hospital Gregorio Marañón Not yet recruiting Madrid, Spain Hospital Clínico de Salamanca Not yet recruiting Salamanca, Spain Hospital La Fe Not yet recruiting Valencia, Spain Less <<
NCT02744612 Recurrent Hodgkin Lymphoma ... More >> Refractory Hodgkin Lymphoma Less << Phase 2 Recruiting December 2018 United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Robert W. Chen, MD    626-256-4673       Principal Investigator: Robert W. Chen, MD          University of California San Diego Not yet recruiting La Jolla, California, United States, 92093 Contact: Carolyn M. Mulroney, MD    858-822-6600       Principal Investigator: Carolyn M. Mulroney, MD          United States, New York Weill Medical College of Cornell University Not yet recruiting New York, New York, United States, 10065 Contact: Peter Martin, MD    646-962-2064       Principal Investigator: Peter Martin, MD          United States, Ohio Ohio State University Comprehensive Cancer Center Not yet recruiting Columbus, Ohio, United States, 43210 Contact: Kami Maddocks, MD    614-688-7942       Principal Investigator: Kami Maddocks, MD Less <<
NCT03013933 Recurrent Hodgkin Lymphoma ... More >> Refractory Hodgkin Lymphoma CD30-Positive Neoplastic Cells Present Less << Phase 1 Recruiting March 2019 United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Robert W. Chen, MD    626-256-4673 ext 64762    rchen@coh.org    Principal Investigator: Robert W. Chen, MD Less <<
NCT01290549 Non-Hodgkins Lymphoma ... More >> Chronic Lymphocytic Leukemia Less << Phase 1 Completed - United States, California ... More >> Stanford Cancer Center Stanford, California, United States, 94305-5820 Stanford Cancer Institute Pharmacy Stanford, California, United States, 94305 United States, Florida Florida Cancer Specialists; Sarasota Sarasota, Florida, United States, 34232 United States, New York Roswell Park Cancer Inst. Buffalo, New York, United States, 14263 United States, Tennessee Sarah Cannon Cancer Center Germantown, Tennessee, United States, 38138 United States, Texas M.D Anderson Cancer Center; Oncology Houston, Texas, United States, 77030 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 Canada, Alberta Cross Cancer Institute ; Dept of Medical Oncology Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia British Columbia Cancer Agency Vancouver, British Columbia, Canada, V5Z 1H6 Canada, Quebec McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology Montreal, Quebec, Canada, H3T 1E2 France CHU Dijon - SCE Hemato Dijon, France, 21000 Centre Hospitalier Regional Universitaire de Lille Lille, France CHU Lapeyronie, Hematologie Montpellier, France, 34295 Centre Hospitalier Lyon Sud; Hematolgie Pierre Benite, France, 69495 Centre Henri Becquerel; Hematologie Rouen, France, 76038 Netherlands Academisch Medisch Centrum; Hematologie Amsterdam, Netherlands, 1105 AZ Less <<
NCT03729609 - Recruiting May 31, 2022 Japan ... More >> Takeda Selected Site Recruiting Tokyo, Japan Less <<
NCT01578967 Hodgkin Lymphoma, Adult Not Applicable Active, not recruiting August 10, 2021 United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, North Carolina University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 Levine Cancer Istitute, Carolinas Health Care system Charlotte, North Carolina, United States, 28204 Rex Cancer Center Raleigh, North Carolina, United States, 27607 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37240 Less <<
NCT01771107 AIDS-Related Hodgkin Lymphoma ... More >> Ann Arbor Stage II Hodgkin Lymphoma Ann Arbor Stage IIA Hodgkin Lymphoma Ann Arbor Stage IIB Hodgkin Lymphoma Ann Arbor Stage III Hodgkin Lymphoma Ann Arbor Stage IIIA Hodgkin Lymphoma Ann Arbor Stage IIIB Hodgkin Lymphoma Ann Arbor Stage IV Hodgkin Lymphoma Ann Arbor Stage IVA Hodgkin Lymphoma Ann Arbor Stage IVB Hodgkin Lymphoma Classic Hodgkin Lymphoma HIV Infection Less << Phase 1 Phase 2 Recruiting December 12, 2019 United States, California ... More >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          UCLA Center for Clinical AIDS Research and Education Recruiting Los Angeles, California, United States, 90035 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Scott D. Christensen    916-734-3771    schristensen@ucdavis.edu    Principal Investigator: Scott D. Christensen          United States, Florida University of Miami Miller School of Medicine-Sylvester Cancer Center Recruiting Miami, Florida, United States, 33136 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          United States, Illinois John H Stroger Jr Hospital of Cook County Recruiting Chicago, Illinois, United States, 60612 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          United States, Louisiana Louisiana State University Health Science Center Recruiting New Orleans, Louisiana, United States, 70112 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          United States, Massachusetts Boston Medical Center Recruiting Boston, Massachusetts, United States, 02118 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          Beth Israel Deaconess Medical Center Active, not recruiting Boston, Massachusetts, United States, 02215 United States, Missouri Siteman Cancer Center at Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          Washington University - Jewish Recruiting Saint Louis, Missouri, United States, 63110 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          United States, New York Montefiore Medical Center-Einstein Campus Recruiting Bronx, New York, United States, 10461 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          United States, Pennsylvania Pennsylvania Oncology Hematology Associates Recruiting Philadelphia, Pennsylvania, United States, 19106 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          United States, Washington Virginia Mason Medical Center Recruiting Seattle, Washington, United States, 98101 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          Harborview Medical Center Recruiting Seattle, Washington, United States, 98104 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          Fred Hutchinson Cancer Research Center Recruiting Seattle, Washington, United States, 98109 Contact: Paul G. Rubinstein    312-864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein          France Centre Hospitalier Universitaire (CHU) de Toulouse Recruiting Cedex, France, 31059 Contact: Pierre Delobel    33-5-6177-7508    delobel.p@chu-toulouse.fr    Principal Investigator: Pierre Delobel          Hopital Antoine Beclere Recruiting Clamart, France, 92140 Contact: Francois Boue    33-1-4537-4409    francois.boue@abc.aphp.fr    Principal Investigator: Francois Boue          Henri Mondor University-Hospital Center Recruiting Creteil, France, 94000 Contact: Corinne Haioun    33-1-49-81-20-51    corinne.haioun@hmn.aphp.fr    Principal Investigator: Corinne Haioun          Hopital l'Archet-CHU de Nice Recruiting Nice, France, 06202 Contact: Nicolas Mounier    334-9203-5841    mounier.n@chu-nice.fr    Principal Investigator: Nicolas Mounier          Hopital Saint Louis Recruiting Paris, France, 75010 Contact: Eric Oksenhendler    33-1-4249-9811    eric.oksenhendler@sls.aphp.fr    Principal Investigator: Eric Oksenhendler          Hospital Saint-Antoine Recruiting Paris, France, 75012 Contact: Paul Coppo    33-1-4928-2616    paul.coppo@sat.aphp.fr    Principal Investigator: Paul Coppo          Centre Hospitalier Lyon-Sud Recruiting Pierre Benite, France, 69310 Contact: Gilles Salles    33-(0)-4-78-86-43-02    gilles.salles@chu-lyon.fr    Principal Investigator: Gilles Salles          Chu Purpan Recruiting Toulouse, France, 31059 Contact: Paul G. Rubinstein    (312) 864-7277    prubinstein@cookcountyhhs.org    Principal Investigator: Paul G. Rubinstein Less <<
NCT02086604 Lymphoma, Large B-Cell, Diffus... More >>e Less << Phase 1 Active, not recruiting November 30, 2019 United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Ohio State University, James Cancer Hospital Columbus, Ohio, United States, 43210 Less <<
NCT01578967 - Active, not recruiting - -
NCT02505269 Hodgkin Lymphoma Phase 2 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT02689219 Germ Cell Tumors ... More >> Testis Cancer Testicular Cancer Embryonal Carcinoma Nonseminomatous Germ Cell Tumor Less << Phase 2 Recruiting December 31, 2019 United States, California ... More >> USC/Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Charis Barg, RN    323-865-0845    charis.barg@med.usc.edu    Principal Investigator: David Quinn, MD          United States, Indiana Indiana University Health Hospital Recruiting Indianapolis, Indiana, United States, 46202 Contact: Yvonne LaFary, RN    317-278-5613    ylafary@iu.edu    Principal Investigator: Costantine Albany, MD          Indiana University Health Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Yvonne LaFary, RN    317-278-5613    ylafary@iu.edu    Principal Investigator: Costantine Albany, MD          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Darren R. Feldman, MD    646-422-4491    feldman@mskcc.org    Principal Investigator: Darren R. Feldman, MD          United States, Utah Intermountain Precision Genomics Cancer Research Clinic Withdrawn Murray, Utah, United States, 84107 Less <<
NCT03473691 Triple Negative Breast Cancer Early Phase 1 Withdrawn(Pharmaceutical compa... More >>ny decided to withdraw funding and not provide drug.) Less << May 1, 2018 -
NCT01902160 Recurrent Adult Hodgkin Lympho... More >>ma Less << Phase 1 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01620229 Hematopoietic/Lymphoid Cancer Phase 1 Phase 2 Withdrawn - United States, Washington ... More >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less <<
NCT01703949 CD30-Positive Neoplastic Cells... More >> Present Recurrent Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Refractory Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Less << Phase 2 Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Ajay K. Gopal    206-606-2037    agopal@u.washington.edu    Principal Investigator: Ajay K. Gopal Less <<
NCT02298257 HIV Infection ... More >> HIV-associated Hodgkin Lymphoma Stage III Adult Hodgkin Lymphoma Stage IV Adult Hodgkin Lymphoma Less << Phase 2 Active, not recruiting December 2019 France ... More >> APHP - Hôpital Antoine Béclère Clamart, France, 92140 CHU de Nice Nice, France, 06202 APHP - Hôpital Saint Antoine Paris Cedex 12, France, 75571 Hopital St Louis Paris, France, 75475 Centre Hospitalier Lyon Sud Pierre Bénite, France, 69495 CHU de Toulouse Toulouse, France Less <<
NCT01026233 Disease, Hodgkin ... More >> Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin Less << Phase 1 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294-3300 United States, California City of Hope National Medical Center Duarte, California, United States, 91010 Stanford Cancer Center Stanford, California, United States, 94305 United States, Florida University of Miami Hospital and Clinics, Miller School of Medicine Miami, Florida, United States, 33136 United States, Illinois Cardinal Bernardin Cancer Center / Loyola University Medical Center Maywood, Illinois, United States, 60153 United States, New York New York University Cancer Institute New York, New York, United States, 10016 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 Germany University Hospital of Cologne Koln, Germany, 50924 Less <<
NCT02758717 Ann Arbor Stage IB Hodgkin Lym... More >>phoma Ann Arbor Stage II Hodgkin Lymphoma Ann Arbor Stage IIA Hodgkin Lymphoma Ann Arbor Stage IIB Hodgkin Lymphoma Ann Arbor Stage III Hodgkin Lymphoma Ann Arbor Stage IIIA Hodgkin Lymphoma Ann Arbor Stage IIIB Hodgkin Lymphoma Ann Arbor Stage IV Hodgkin Lymphoma Ann Arbor Stage IVA Hodgkin Lymphoma Ann Arbor Stage IVB Hodgkin Lymphoma Classic Hodgkin Lymphoma Less << Phase 2 Recruiting May 13, 2024 United States, California ... More >> Stanford Cancer Institute Palo Alto Recruiting Palo Alto, California, United States, 94304 Contact: Ann Moffat    650-721-4096    amoffat@stanford.edu    Principal Investigator: Ranjana H. Advani          United States, District of Columbia MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 Contact: Pari Ramzi    202-784-0038    ramzip1@georgetown.edu    Principal Investigator: Bruce D. Cheson          United States, Illinois University of Chicago Comprehensive Cancer Center Withdrawn Chicago, Illinois, United States, 60637 United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mayo Clinic Clinical Trials Office    507-538-7623    clinicaltrials@mayo.edu    Principal Investigator: Stephen M. Ansell          United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Kelly Hoye    314-362-4206    khoye@wustl.edu    Principal Investigator: Nancy L. Bartlett          United States, New Jersey Hackensack University Medical Center Recruiting Hackensack, New Jersey, United States, 07601 Contact: Kara M. Yannotti    551-996-5900    Kara.Yannotti@HackensackMeridian.org    Principal Investigator: Tatyana A. Feldman          United States, New York Laura and Isaac Perlmutter Cancer Center at NYU Langone Recruiting New York, New York, United States, 10016 Contact: Mohammad Maher Abdul-Hay    212-731-5670    Maher.Abdulhay@nyumc.org    Principal Investigator: Catherine S. Diefenbach          United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Rashmeet Reen    614-688-9283    rashmeet.reen@osumc.edu    Principal Investigator: Kristie A. Blum          United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Emily Wesson    713-794-5656    etwesson@mdanderson.org    Principal Investigator: Michelle A. Fanale Less <<
NCT02616965 Cutaneous T-cell Lymphoma (CTC... More >>L) Less << Phase 1 Recruiting July 2021 United States, Pennsylvania ... More >> Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Stefan K. Barta, MD    215-728-2674       Principal Investigator: Stefan K. Barta, MD Less <<
NCT03057795 Classical Hodgkin Lymphoma ... More >> Hematopoietic Cell Transplantation Recipient Recurrent Hodgkin Lymphoma Refractory Hodgkin Lymphoma Less << Phase 2 Recruiting October 2019 United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Alex Herrera, MD    626-256-4673    aherrera@coh.org    Principal Investigator: Alex Herrera          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office https://www.mayo.edu/research/forms/cancer-clinical-trials    855-776-0015       Principal Investigator: Patrick B. Johnston, MD          United States, New Jersey Hackensack University Medical Center Not yet recruiting Hackensack, New Jersey, United States, 07601 Contact: Alan P. Skarbnik    212-996-5900    Alan.Skarbnik@hackensackmeridian.org    Principal Investigator: Alan P. Skarbnik          United States, New York Memorial Sloan-Kettering Cancer Center Not yet recruiting New York, New York, United States, 10065 Contact: Gunjan L. Shah       shahg@mskcc.org    Principal Investigator: Gunjan L. Shah          United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Yago L. Nieto    713-792-8750    ynieto@mdanderson.org    Principal Investigator: Yago L. Nieto          United States, Washington Fred Hutchinson Cancer Research Center Not yet recruiting Seattle, Washington, United States, 98109 Contact: Leona A. Holmberg    206-288-2035    lholmber@fredhutch.org    Principal Investigator: Leona A. Holmberg Less <<
NCT02363283 Recurrent Uveal Melanoma ... More >> Stage IV Uveal Melanoma AJCC v7 Less << Phase 2 Completed - -
NCT03409432 Lymphomatoid Papulosis ... More >> Primary Cutaneous Anaplastic Large Cell Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent T-Cell Non-Hodgkin Lymphoma Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma Less << Phase 2 Recruiting April 30, 2020 United States, Ohio ... More >> Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Basem M. William, MD    614-688-7942    basem.william@osumc.edu    Principal Investigator: Basem M. William, MD Less <<
NCT01992653 Lymphoma, Non Hodgkin Phase 1 Phase 2 Active, not recruiting January 25, 2019 United States, Alabama ... More >> The University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 United States, Arizona Banner MD Anderson Cancer Center Gilbert, Arizona, United States, 85234 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Missouri Washington University; Pediatrics Saint Louis, Missouri, United States, 63110 United States, Oregon Northwest Cancer Specialists Portland, Oregon, United States, 97210 Oregon Health and Science University Portland, Oregon, United States, 97239 Willamette Valley Clinical Studies; Cancer Institute Springfield, Oregon, United States, 97477 United States, Texas Cancer Care Centers of South Texas San Antonio, Texas, United States, 78212 United States, Virginia Blue Ridge Cancer Care Roanoke, Virginia, United States, 24014 United States, Washington Northwest Medical Specialties, PLLC; Research Department Tacoma, Washington, United States, 98405 France Hopital Henri Mondor, Unite Hemopathies lymphoides Creteil, France, 94010 Hopital Claude Huriez - CHU Lille; Service des maladies du sang Lille, France, 59037 Hopital Haut-Leveque - Centre Francois Magendie; Service d'Hematologie Clinique Pessac, France, 33604 Centre Hospitalier Lyon Sud; Hematolgie Pierre Benite, France, 69495 Hopital Pontchaillou - CHU de Rennes Rennes, France, 35033 Centre Henri Becquerel; Hematologie Rouen, France, 76038 Less <<
NCT02487979 Recurrent Osteosarcoma Phase 2 Completed - -
NCT03373305 CD30-Positive Neoplastic Cells... More >> Present Folliculotropic Mycosis Fungoides Recurrent Mycosis Fungoides Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Mycosis Fungoides Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Sezary Syndrome Less << Phase 1 Not yet recruiting December 2020 United States, California ... More >> City of Hope Medical Center Not yet recruiting Duarte, California, United States, 91010 Contact: Jasmine Zain, MD          Principal Investigator: Jasmine Zain, MD Less <<
NCT02729961 Anaplastic Large Cell Lymphoma... More >>, ALK-Positive CD30-Positive Neoplastic Cells Present Systemic Anaplastic Large Cell Lymphoma Less << Phase 1 Phase 2 Recruiting July 1, 2023 United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Andrei R. Shustov    206-606-6744    ashustov@u.washington.edu    Principal Investigator: Andrei R. Shustov Less <<
NCT01874054 Hodgkin Disease Phase 1 Phase 2 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, California Pacific Hematology Oncology Associates San Francisco, California, United States, 94115 Stanford Cancer Center Stanford, California, United States, 94305 Oncology Institute of Hope & Innovation, The Whittier, California, United States, 90603 United States, Colorado Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic Minnesota Rochester, Minnesota, United States, 55905 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-7680 United States, New York Columbia University Medical Center New York, New York, United States, 10022 United States, Ohio Jewish Hospital, The Cincinnati, Ohio, United States, 45236 Case Western Reserve University / University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 United States, South Carolina Saint Francis Hospital / Bon Secours Greenville, South Carolina, United States, 29601 United States, Texas Charles A. Sammons Cancer Center / Baylor University Medical Center Dallas, Texas, United States, 75246 Less <<
NCT03496779 Refractory Peripheral T-Cell L... More >>ymphoma Relapsed Peripheral T-Cell Lymphoma Less << Phase 2 Recruiting October 2022 Belgium ... More >> ZNA Stuivenberg Recruiting Antwerpen, Belgium, 2060 Contact: Ka Lung WU, MD          A. Z. Sint-Jan Recruiting Bruges, Belgium, 8000 Contact: Sylvia SNAUWAERT, MD          Clinique Universitaire Saint LUC Recruiting Brussels, Belgium, 1200 Contact: Eric VAN DEN NESTE, Pr          Institut Jules Bordet Recruiting Brussels, Belgium Contact: Marie MAEREVOET, MD          ULB Hôpital Erasme Recruiting Brussels, Belgium Contact: Virginie DE WILDE, MD          UZ Gent Recruiting Gent, Belgium, 9000 Contact: Fritz OFFNER, MD          CHU de Liege Recruiting Liege, Belgium, 4000 Contact: Christophe BONNET, MD          CHU UCL Namur Recruiting Yvoir, Belgium Contact: Marc ANDRE, MD          France IHBN - CHU Cote de Nacre Recruiting Amiens, France, 80054 Contact: Ghandi DAMAJ, MD          CHU d'Amiens Recruiting Amiens, France Contact: Caroline DELETTE, MD          CHU Angers Recruiting Angers, France, 49033 Contact: Marie-Pierre MOLES-MOREAU, MD          CH d'Avignon - Hôpital Henri Dufaut Recruiting Avignon, France, 84000 Contact: Hacene ZERAZHI, MD          CH Côte Basque Recruiting Bayonne, France, 64100 Contact: Anne BANOS, MD          CHU de Besançon - Hôpital Jean Minjoz Recruiting Besançon, France, 25030 Contact: Adrien CHAUCHET, MD          CH Chambéry Recruiting Chambery, France, 73011 Contact: Maya Hacini, MD          CHU d'Estaing Recruiting Clermont-Ferrand, France, 63000 Contact: Sebastien BAILLY, MD          APHP - Hopital Henri Mondor Recruiting Creteil, France, 94010 Contact: Jehan DUPUIS, MD          CHU de Dijon - Hôpital le Bocage Recruiting Dijon, France, 21000 Contact: Olivier CASASNOVAS, MD          CHU Grenoble Recruiting Grenoble, France, 38043 Contact: Remy GRESSIN, MD          CH de Versailles - Hopital André Mignot Recruiting Le Chesnay, France, 78157 Contact: Hassan Farhat, MD          CH du Mans Recruiting Le Mans, France, 72000 Contact: Kamel LARIBI, Dr          CHRU de Lille - Hôpital Claude Huriez Recruiting Lille, France Contact: Franck MORSCHHAUSER, Pr          CHU de Limoges Recruiting Limoges, France Contact: Arnaud JACCARD, MD          Centre Leon Berard Recruiting Lyon Cedex 8, France, 69373 Contact: Emmanuelle NICOLAS-VIRELIZIER, MD          Institut Paoli Calmettes Withdrawn Marseille, France, 13000 Centre Hospitalier Annecy Genevois Recruiting Metz-Tessy, France, 74374 Contact: Nicolas DAGUINDAU, MD          CH Saint-Eloi Recruiting Montpellier, France, 34295 Contact: Guillaume CARTRON, MD    04 67 33 83 62       Principal Investigator: Guillaume CARTRON, MD          CH de Mulhouse Sud Alsace Recruiting Mulhouse, France, 68070 Contact: Bernard DRENOU, MD          CHU Nancy - Brabois Recruiting Nancy, France, 54511 Contact: Pierre Feugier, MD          CHU de Nantes - Hôtel Dieu Recruiting Nantes, France, 44093 Contact: Steven LE GOUILL, Pr          APHP - Hôpital Saint Louis Recruiting Paris Cedex 10, France, 75475 Contact: Catherine Thieblemont, MD          APHP - Hôpital Necker Recruiting Paris, France, 75015 Contact: Richard Delarue, MD          Centre François Magendie - Hôpital du Haut Lévêque Recruiting Pessac, France, 33604 Contact: Kamal BOUABDALLAH, MD          Centre Hospitalier Lyon Sud Recruiting Pierre Bénite, France, 69495 Contact: Emmanuel BACHY, MD          CHU de Poitiers - Hôpital de la Milétrie Recruiting Poitiers, France, 86021 Contact: Vincent DELWAIL, MD          CHU De Rennes Recruiting Rennes, France, 35033 Contact: Thierry LAMY DE LA CHAPELLE, MD          Centre Henri BECQUEREL Recruiting Rouen, France, 76038 Contact: Hervé TILLY, Pr          CHU de Toulouse Recruiting Toulouse, France, 31059 Contact: Loïc Ysebaert, MD          CHRU de Tours Recruiting Tours, France, 37044 Contact: Emmanuel Gyan, MD          CH de Valenciennes Recruiting Valenciennes, France, 59322 Contact: Sabine TRICOT, MD Less <<
NCT02096042 Leukemia Phase 1 Phase 2 Terminated(Slow accrual.) - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02169505 Lymphoma Phase 2 Terminated(Slow Accrual) - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03657043 Ovarian Cancer ... More >> Fallopian Tube Cancer Peritoneal Cancer Less << Phase 2 Not yet recruiting September 2021 -
NCT02096042 - Terminated(Slow accrual.) - -
NCT01950364 Hodgkin Lymphoma ... More >> Anaplastic Large-cell Lymphoma Less << Phase 1 Completed - Belgium ... More >> Brussels, Belgium Gent, Belgium Lithuania Vilnius, Lithuania Spain Barcelona, Spain Madrid, Spain Salamanca, Spain Less <<
NCT01874054 - Completed - -
NCT02988843 Germ Cell Tumor Phase 2 Suspended(Funding Unavailable) February 2021 United States, Minnesota ... More >> University of Minnesota Minneapolis, Minnesota, United States, 55455 Less <<
NCT01900496 Lymphoma Phase 1 Terminated(Low accrual) - United States, Maryland ... More >> The Sidney Kimmel Comprehensive Canceer Center Baltimore, Maryland, United States, 21287 Less <<
NCT01950364 - Completed - -
NCT01830777 Acute Myelogenous Leukemia Phase 1 Active, not recruiting December 2019 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT02487979 - Completed - -
NCT01461538 Acute Lymphoid Leukemia ... More >> Acute Myeloid Leukemia Anemia, Refractory, With Excess of Blasts Solid Tumors Less << Phase 2 Completed - -
NCT01461538 - Completed - -
NCT02552121 Ovary Cancer ... More >>Cervix Cancer Endometrium Cancer Bladder Cancer Prostate Cancer (CRPC) Esophagus Cancer Lung Cancer (NSCLC) Less << Phase 1 Phase 2 Completed - United States, Texas ... More >> MD Anderson Cancer Center Houston, Texas, United States, 77030 Belgium Institut Jules Bordet Bruxelles, Brussels, Belgium, 1000 Universitaire Ziekenhuizen Leuven Leuven, Flemish Brabant, Belgium, 3000 Grand Hôpital de Charleroi Charleroi, Hainaut, Belgium, 6000 CHU de Liège Liege, Liège, Belgium, 4000 CHU UCL Namur - site Godinne Yvoir, Namur, Belgium, 5530 Cliniques Universitaires Saint-Luc Brussels, Belgium, 1200 CHU UCL Namur - Sainte Elisabeth Namur, Belgium, 5000 Denmark Rigshospitalet, Copenhagen University Hospital Copenhagen, Denmark, DK-2100 Hungary Petz Aladár Megyei Oktató Kórház Gyor, Gyor-Moson-Sopron, Hungary, 9023 Debreceni Egyetem Klinikai Központ Debrecen, Hajdu-Bihar, Hungary, 4032 Semmelweis Egyetem Onkológiai Központ Budapest, Hungary, 1083 United Kingdom University College London Hospitals NHS Foundation Trust London, England, United Kingdom, NW1 2PG Sarah Cannon Cancer Center London, England, United Kingdom, W1G 6AD The Christie NHS Foundation Trust Manchester, England, United Kingdom, M20 4BX The Royal Marsden NHS Foundation Trust Sueery, United Kingdom, SM2 5PT Less <<
NCT02572167 Hodgkin Lymphoma Phase 1 Phase 2 Active, not recruiting October 2020 United States, California ... More >> City of Hope National Medical Center Duarte, California, United States, 91010-3000 Stanford Cancer Center Stanford, California, United States, 94305 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Karmanos Cancer Institute / Wayne State University Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Minnesota Rochester, Minnesota, United States, 55905 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-7680 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Memorial Sloan Kettering Cancer Center - Commack Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10021 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio James Cancer Hospital / Ohio State University Columbus, Ohio, United States, 43210 United States, Texas Charles A. Sammons Cancer Center / Baylor University Medical Center Dallas, Texas, United States, 75246 Less <<
NCT03326258 Advanced Malignant Solid Neopl... More >>asm Estrogen Receptor Negative GPNMB Positive HER2/Neu Negative Metastatic Malignant Solid Neoplasm Metastatic Melanoma Progesterone Receptor Negative Stage III Breast Cancer AJCC v7 Stage III Cutaneous Melanoma AJCC v7 Stage III Uveal Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Stage IV Uveal Melanoma AJCC v7 Triple-Negative Breast Carcinoma Unresectable Solid Neoplasm Less << Phase 1 Phase 2 Withdrawn(The study itself was... More >> Disapproved on 04/20/2018 and will not be moving forward.) Less << - -
NCT02302339 Melanoma Phase 2 Terminated(Development of glem... More >>batumumab vedotin was discontinued) Less << - United States, California ... More >> The Angeles Clinic and Research Institute Los Angeles, California, United States, 90025 Northern California Melanoma Center/St. Mary's Medical Center San Francisco, California, United States, 94117 United States, Florida Florida Cancer Specialists Fort Myers, Florida, United States, 33916 Mount Sinai Comprehensive Cancer Center Miami Beach, Florida, United States, 33140 Florida Cancer Specialists West Palm Beach, Florida, United States, 33407 United States, Georgia Northside Hospital Cancer Institute Atlanta, Georgia, United States, 30341 United States, Illinois University of Chicago Medicine Chicago, Illinois, United States, 60637 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, New York New York University School of Medicine New York, New York, United States, 10016 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Tennessee Tennessee Oncology Nashville, Tennessee, United States, 37203 Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas Baylor Research Institute-Sammons Cancer Center Dallas, Texas, United States, 75246 Less <<
NCT03438396 Cervical Cancer Phase 2 Recruiting April 2023 -
NCT02581631 Non-Hodgkin's Disease Phase 1 Phase 2 Recruiting February 13, 2020 -
NCT01657331 Hodgkin Lymphoma ... More >> Anaplastic Large Cell Lymphoma Less << Phase 1 Phase 2 Active, not recruiting April 2019 United States, New York ... More >> Columbia University Medical Center New York, New York, United States, 10019 Canada, British Columbia British Columbia Cancer Agency Vancouver, British Columbia, Canada, V5z 4E6 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada Less <<
NCT02533570 Systemic Lupus Erythematosus Phase 2 Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less << - United States, Alabama ... More >> University of Alabama at Birmingham - (UAB) Birmingham, Alabama, United States, 35294 United States, California TriWest Research Associates, LLC El Cajon, California, United States, 92020-4124 Advanced Medical Research, LLC La Palma, California, United States, 90623 United States, Colorado University of Colorado Aurora, Colorado, United States, 80045 United States, Florida Clinical Research of West Florida - Corporate Clearwater, Florida, United States, 33765 Lakes Research, LLC Miami Lakes, Florida, United States, 33014 Arthritis Associates Orlando, Florida, United States, 32804 McIlwain Medical Group Tampa, Florida, United States, 33613 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 United States, Missouri Clayton Medical Associates, P.C. Saint Louis, Missouri, United States, 63117 United States, New York Weill Cornell Physicians at Brooklyn Heights Brooklyn, New York, United States, 11201 United States, North Carolina DJL Clinical Research, PLLC Charlotte, North Carolina, United States, 28210 United States, Oklahoma Arthritis & Rheumatology Center of Oklahoma Oklahoma City, Oklahoma, United States, 73103 United States, Tennessee Ramesh C Gupta MD Memphis, Tennessee, United States, 38119 United States, Texas Tekton Research, Inc. Austin, Texas, United States, 78745 Accurate Clinical Research Houston, Texas, United States, 77034 United States, Virginia Arthritis Clinic of Northern Virginia, PC Arlington, Virginia, United States, 22205-3606 Less <<
NCT02254239 Recurrent Hodgkin Lymphoma ... More >> Refractory Hodgkin Lymphoma Less << Phase 1 Suspended(Per study design) September 30, 2020 United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT02533570 - Terminated(Sponsor decision ba... More >>sed on portfolio prioritization) Less << - -
NCT01805037 Adult Grade III Lymphomatoid G... More >>ranulomatosis Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Contiguous Stage II Adult Burkitt Lymphoma Contiguous Stage II Adult Diffuse Large Cell Lymphoma Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma Contiguous Stage II Adult Lymphoblastic Lymphoma Contiguous Stage II Grade 1 Follicular Lymphoma Contiguous Stage II Grade 2 Follicular Lymphoma Contiguous Stage II Grade 3 Follicular Lymphoma Contiguous Stage II Mantle Cell Lymphoma Contiguous Stage II Marginal Zone Lymphoma Contiguous Stage II Small Lymphocytic Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Epstein-Barr Virus Infection Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Hepatosplenic T-cell Lymphoma Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Noncontiguous Stage II Adult Burkitt Lymphoma Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma Noncontiguous Stage II Adult Lymphoblastic Lymphoma Noncontiguous Stage II Grade 1 Follicular Lymphoma Noncontiguous Stage II Grade 2 Follicular Lymphoma Noncontiguous Stage II Grade 3 Follicular Lymphoma Noncontiguous Stage II Mantle Cell Lymphoma Noncontiguous Stage II Marginal Zone Lymphoma Noncontiguous Stage II Small Lymphocytic Lymphoma Noncutaneous Extranodal Lymphoma Peripheral T-cell Lymphoma Post-transplant Lymphoproliferative Disorder Progressive Hairy Cell Leukemia, Initial Treatment Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Refractory Hairy Cell Leukemia Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Stage I Adult Burkitt Lymphoma Stage I Adult Diffuse Large Cell Lymphoma Stage I Adult Diffuse Mixed Cell Lymphoma Stage I Adult Diffuse Small Cleaved Cell Lymphoma Stage I Adult Hodgkin Lymphoma Stage I Adult Immunoblastic Large Cell Lymphoma Stage I Adult Lymphoblastic Lymphoma Stage I Adult T-cell Leukemia/Lymphoma Stage I Cutaneous T-cell Non-Hodgkin Lymphoma Stage I Grade 1 Follicular Lymphoma Stage I Grade 2 Follicular Lymphoma Stage I Grade 3 Follicular Lymphoma Stage I Mantle Cell Lymphoma Stage I Marginal Zone Lymphoma Stage I Small Lymphocytic Lymphoma Stage IA Mycosis Fungoides/Sezary Syndrome Stage IB Mycosis Fungoides/Sezary Syndrome Stage II Adult Hodgkin Lymphoma Stage II Adult T-cell Leukemia/Lymphoma Stage II Cutaneous T-cell Non-Hodgkin Lymphoma Stage IIA Mycosis Fungoides/Sezary Syndrome Stage IIB Mycosis Fungoides/Sezary Syndrome Stage III Adult Burkitt Lymphoma Stage III Adult Diffuse Large Cell Lymphoma Stage III Adult Diffuse Mixed Cell Lymphoma Stage III Adult Diffuse Small Cleaved Cell Lymphoma Stage III Adult Hodgkin Lymphoma Stage III Adult Immunoblastic Large Cell Lymphoma Stage III Adult Lymphoblastic Lymphoma Stage III Adult T-cell Leukemia/Lymphoma Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma Stage III Grade 3 Follicular Lymphoma Stage III Mantle Cell Lymphoma Stage III Marginal Zone Lymphoma Stage III Small Lymphocytic Lymphoma Stage IIIA Mycosis Fungoides/Sezary Syndrome Stage IIIB Mycosis Fungoides/Sezary Syndrome Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Adult T-cell Leukemia/Lymphoma Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Small Lymphocytic Lymphoma Stage IVA Mycosis Fungoides/Sezary Syndrome Stage IVB Mycosis Fungoides/Sezary Syndrome T-cell Large Granular Lymphocyte Leukemia Testicular Lymphoma Untreated Hairy Cell Leukemia Waldenstr?m Macroglobulinemia Less << Phase 1 Phase 2 Unknown - United States, Illinois ... More >> Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Adam M. Petrich, MD    312-695-6180    apetrich@nmff.org    Principal Investigator: Adam M. Petrich, MD          Sub-Investigator: Leo Gordon, MD          Sub-Investigator: Jane Winter, MD          Sub-Investigator: Shuo Ma, MD, PhD          Sub-Investigator: Steven Rosen, MD          Sub-Investigator: Amy Chadburn, MD          University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Chadi Nabhan, MD    773-702-9574       Principal Investigator: Chadi Nabhan, MD          United States, Massachusetts Tufts University School of Medicine Recruiting Boston, Massachusetts, United States, 02111 Contact: Andrew M. Evens, MD    617-636-8077       Principal Investigator: Andrew M. Evens, MD Less <<
NCT03485209 Colorectal Neoplasms ... More >> Carcinoma, Non-Small-Cell Lung Exocrine Pancreatic Cancer Carcinoma, Squamous Cell of Head and Neck Less << Phase 2 Recruiting April 2021 United States, California ... More >> University of California Davis Recruiting Davis, California, United States, 95616 Contact: Michelle Cregan    916-734-8512    mpcregan@ucdavis.edu    Principal Investigator: May Cho          Stanford Cancer Center / Blood and Marrow Transplant Program Recruiting Stanford, California, United States, 94305 Contact: Ann Moffat    669-233-2816    amoffat@stanford.edu    Principal Investigator: Omid Tehrani          United States, Connecticut Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06520 Contact: Erica Carbone    203-737-4645    erica.carbone@yale.edu    Principal Investigator: Jill Lacy, MD          United States, Florida Shands Cancer Center / University of Florida Recruiting Gainesville, Florida, United States, 32610 Contact: Ashton Monismith    352-265-0680    amonismith@ufl.edu    Principal Investigator: Thomas George, MD          United States, Georgia Winship Cancer Institute / Emory University School of Medicine Recruiting Atlanta, Georgia, United States, 30322 Contact: Monique Guyinn    404-778-1900    monique.guyinn@emory.edu    Principal Investigator: Conor Steuer          United States, Illinois Ingalls Cancer Care / Ingalls Memorial Hospital Recruiting Harvey, Illinois, United States, 60426 Contact: Margaret Marriott    703-339-4800    mmarriott@ingalls.org    Principal Investigator: Kimberly Kruczek, MD          United States, Kansas University of Kansas Cancer Center Recruiting Westwood, Kansas, United States, 66205 Contact: Michelle Cairns    913-945-7547    mcairns3@kumc.edu    Principal Investigator: Anwaar Saeed          United States, Kentucky Norton Cancer Institute Recruiting Louisville, Kentucky, United States, 40202 Contact: Catherine Conway    502-629-4267    catherine.conway@nortonhealthcare.org    Principal Investigator: John Hamm, MD          United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Ketki Bhushan    617-632-4270    Ketki_Bhushan@DFCI.HARVARD.EDU    Principal Investigator: Geoffrey Shapiro          United States, Minnesota HealthPartners Institute Recruiting Saint Louis Park, Minnesota, United States, 55426 Contact: Alissa Gavenda    952-993-6071    Alissa.Gavenda@ParkNicollet.com    Principal Investigator: Daniel Anderson, MD          United States, Oregon Oregon Health and Science University Recruiting Portland, Oregon, United States, 97239-3098 Contact: Zack Godwin    503-494-1617    godwinz@ohsu.edu    Principal Investigator: Matthew Taylor, MD          United States, Rhode Island Rhode Island Hospital Recruiting Providence, Rhode Island, United States, 02903 Contact: John Vatkevich    401-444-6217    John.vatkevich@lifespan.org    Principal Investigator: Howard Safran          United States, Texas MD Anderson Cancer Center / University of Texas Recruiting Houston, Texas, United States, 77030-4095 Contact: Meiyue Hong    713-745-4367    mghong@mdanderson.org    Principal Investigator: David Hong          Joe Arrington Cancer Research and Treatment Center Recruiting Lubbock, Texas, United States, 79410 Contact: Mary Jane Flores    806-725-7993    maryjane.Flores@stjoe.org    Principal Investigator: Isaac Tafur, MD Less <<
NCT03474133 Hodgkin's Lymphoma Phase 2 Not yet recruiting December 2, 2023 -
NCT02979522 Hodgkin Disease Phase 1 Phase 2 Recruiting October 29, 2021 United States, Arkansas ... More >> Arkansas Children's Hospital Recruiting Little Rock, Arkansas, United States, 72202 United States, Colorado Children's Hospital Colorado Recruiting Aurora, Colorado, United States, 80045 United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Childrens Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229-3039 Brazil Hospital Sao Rafael S/A Recruiting Salvador, Bahia, Brazil, 41253-190 INCA - Instituto Nacional de Cancer Recruiting Rio de Janeiro, Rio Do Janeiro, Brazil, 20230-230 Hospital de Clinicas de Porto Alegre Recruiting Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903 Hospital de Cancer de Barretos - Fundacao Pio XII Recruiting Barretos, Sao Paulo, Brazil, 14784-400 Jardim das Americas Recruiting Parana, Brazil, 81520-060 GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer Recruiting Sao Paulo, Brazil, 04023-062 ICr - Instituto da Crianca - HCFMUSP Recruiting Sao Paulo, Brazil, 05403-000 Hospital Santa Marcelina Recruiting Sao Paulo, Brazil, 08270-070 Hong Kong The Chinese University of Hong Kong Recruiting Shatin, Hong Kong, 00000 Italy Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi Recruiting Bologna, Italy, 40138 Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer Recruiting Firenze, Italy, 50139 Fondazione IRCCS Policlinico San Matteo Recruiting Pavia, Italy, 27100 Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia Recruiting Roma, Italy, 165 Azienda Ospedaliera Citta della Salute e della Scienza di Torino Recruiting Torino, Italy, 10126 Japan NHO Nagoya Medical Center Recruiting Nagoya-shi, Aichi-Ken, Japan, 460-0001 Kyushu University Hospital Recruiting Fukuoka-shi, Fukuoka-Ken, Japan, 812-8582 Hokuyukai Sapporo Hokuyu Hospital Recruiting Sapporo-shi, Hokkaido, Japan, 003-0006 St. Marianna University School of Medicine Hospital Recruiting Kawasaki-shi, Kanagawa-Ken, Japan, 216-8511 Singapore National University Cancer Institute Singapore Recruiting Singapore, Singapore, 119228 Taiwan Taichung Veterans General Hospital Recruiting Taichung, Taiwan, 40705 National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Less <<
NCT01578499 Primary Cutaneous Anaplastic L... More >>arge Cell Lymphoma Mycosis Fungoides Cutaneous T-Cell Lymphoma Less << Phase 3 Completed - -
NCT01780662 Recurrent Adult Hodgkin Lympho... More >>ma Recurrent Childhood Hodgkin Lymphoma Refractory Childhood Hodgkin Lymphoma Less << Phase 1 Phase 2 Active, not recruiting - -
NCT01578499 - Completed - -
NCT03222492 Diffuse Cutaneous Systemic Scl... More >>erosis Scleroderma dcSSc Less << Phase 1 Phase 2 Recruiting September 2020 United States, California ... More >> UCLA Medical Center: Division of Rheumatology Recruiting Los Angeles, California, United States, 90095 Contact: Nashla Barroso    310-825-9682    nbarroso@mednet.ucla.edu    Principal Investigator: Suzanne Kafaja, MD          United States, District of Columbia Georgetown University Medical Center: Division of Rheumatology Recruiting Washington, District of Columbia, United States, 20057 Contact: Sabrina Elliott    202-444-6210    sabrina.elliott@georgetown.edu    Principal Investigator: Virginia Steen, MD          United States, Massachusetts Boston University School of Medicine: Rheumatology Section, Scleroderma Clinical Centers Recruiting Boston, Massachusetts, United States, 02118 Contact: Connor Buchholz    617-358-6797    connorbu@bu.edu    Principal Investigator: Robert Simms, MD          United States, Michigan University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Monica Sanborn    734-232-2090    monan@med.umich.edu    Principal Investigator: Vivek Nagaraja, MD          United States, Minnesota Minnesota University of Minnesota, Division of Rheumatology Not yet recruiting Minneapolis, Minnesota, United States, 55455 Principal Investigator: Jerry A. Molitor, MD          United States, New York Hospital for Special Surgery, New York: Division of Rheumatology Recruiting New York, New York, United States, 10021 Contact: Jesse Ojeda    212-774-7620    ojeda@hss.edu    Principal Investigator: Jessica Gordon, MD          United States, North Carolina Duke University Medical Center: Division of Rheumatology and Immunology Recruiting Durham, North Carolina, United States, 27710 Contact: Karissa Grier    919-684-6150    karissa.grier@duke.edu    Principal Investigator: Ankoor Shah, MD          United States, Pennsylvania University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Recruiting Pittsburgh, Pennsylvania, United States, 15217 Contact: Dana Ivanco    412-648-7040    des2@pitt.edu    Principal Investigator: Robert Lafyatis,, MD          United States, South Carolina Medical University of South Carolina: Division of Rheumatology & Immunology Recruiting Charleston, South Carolina, United States, 29425 Contact: Nathan Wilson    843-792-8272    wilsonn@musc.edu    Principal Investigator: Richard Silver, MD          United States, Texas University of Texas Houston Medical School: Division of Rheumatology and Clinical Immunogenetics Recruiting Houston, Texas, United States, 77030 Contact: Pat Gonzales    713-500-7118    patricia.gonzales@uth.tmc.edu    Principal Investigator: Maureen Mayes, MD, MPH          Canada, Ontario Toronto Mount Sinai Hospital Not yet recruiting Toronto, Ontario, Canada, ON M5G 1X5 Contact: Judith Guthrie       judith.guthrie@sinaihealthsystem.ca    Principal Investigator: Sindu R. Johnson, MD,PhD,FRCPC Less <<
NCT02429375 Hodgkin Lymphoma Phase 1 Phase 2 Active, not recruiting April 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT02244021 Relapsed/Refractory Hodgkin's ... More >>Lymphoma Less << Phase 2 Completed - Italy ... More >> Istituto di Ematologia "L. & A. Seragnoli" , Policlinico S. Orsola Malpighi Bologna, Italy Ematologia, IRCCS AOU San Martino-IST Genova, Italy Ematologia Ospedale Vito Fazzi Lecce, Italy Ematologia e Unità BMT IRCCS Istituto Nazionale dei Tumori Milano, Italy Università degli Studi di Modena e Reggio Emilia, D.A.I di Medicina diagnostica clinica e sanità pubblica, AOU Policlinico Modena, Italy Dipartimento di Oncologia Medica ed Ematologia, Istituto Humanitas Rozzano, Italy SC Ematologia - Azienda Ospedaliera AO Città della Salute e della Scienza Torino, Italy Less <<
NCT03219333 Carcinoma, Transitional Cell ... More >> Urinary Bladder Neoplasms Urologic Neoplasms Renal Pelvis Neoplasms Urothelial Cancer Ureteral Neoplasms Urethral Neoplasms Less << Phase 2 Recruiting May 2025 -
NCT01700751 Leukemia, Acute Myeloid ... More >> Leukemia, Lymphoblastic,Acute Myelodysplastic Syndromes Less << Phase 1 Active, not recruiting January 31, 2020 United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT01396070 Non-Hodgkin Lymphoma (NHL)|Cut... More >>aneous Lymphoma|Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides|Sezary Syndrome Less << PHASE2 COMPLETED 2025-05-16 Stanford University School of ... More >>Medicine, Stanford, California, 94305, United States Less <<
NCT02462538 ALK+ Anaplastic Large Cell Lym... More >>phoma Less << Phase 1 Phase 2 Recruiting June 2021 Austria ... More >> Universitätsklinik für Innere Medizin V Recruiting Innsbruck, Austria, A-6020 Contact: Angelina Rauth    0043512504 ext 23382    studienambulanz.haematologie@uki.at    Principal Investigator: Wolfgang Willenbacher, Dr          AKH Linz, Innere Medizin 3, Zentrum f. Haematologie u. med. Onkologie Recruiting Linz, Austria, A-4021 Contact: Bettina Pfleger    +43 7327806 ext 6207    bettina.pfleger@akh.linz.at    Contact: Elisabeth Morbitzer    +43 7327806 ext 6204    elisabeth.morbitzer@akh.linz.at    Principal Investigator: Michael A. Fridrik, Univ.Doz.Dr          Universitätsklinik der PMU, Universitätsklinik für Innere Medizin III Recruiting Salzburg, Austria, 5020 Contact: Michaela Schachner, Mag.    +43 662 4482 ext 2847    m.schachner@salk.at    Principal Investigator: Richard Greil, Univ.Prof.Dr          Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie Recruiting Wien, Austria, 1090 Contact: Natascha Vydra    + 43 1 40400 ext 44100    natascha.vydra@meduniwien.ac.at    Principal Investigator: Ulrich Jäger, Univ.Prof.Dr Less <<
NCT01616680 Graft Versus Host Disease Phase 2 Withdrawn - United States, Washington ... More >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less <<
NCT03539536 Non-small Cell Lung Cancer Phase 2 Recruiting December 10, 2021 -
NCT02497131 Lymphatic Diseases Phase 2 Recruiting December 2021 Italy ... More >> Ematologia "L. & A. Seragnoli" - Policlinico S. Orsola Malpighi Recruiting Bologna, Italy, 40138 Contact: Vittorio Stefoni, MD    +39.0516363680    vittorio.stefoni2@unibo.it    A.O.Spedali civili di Brescia Not yet recruiting Brescia, Italy Principal Investigator: Giuseppe Rossi, MD          Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori Recruiting Milano, Italy Principal Investigator: Paolo Corradini, MD          SC Ematologia - Città della Salute e della Scienza Recruiting Torino, Italy, 10126 Principal Investigator: Umberto Vitolo, MD          A.O. Universitaria S. Maria Della Misericordia Di Udine Recruiting Udine, Italy, 33100 Principal Investigator: Stefano Volpetti, MD Less <<
NCT03187210 Lymphoma Phase 1 Phase 2 Recruiting June 2022 Switzerland ... More >> Department for Medical Oncology University Hospital/Inselspital Recruiting Berne, Switzerland, 3010 Principal Investigator: Thomas Pabst, Prof Dr med Less <<
NCT02423291 Primary Mediastinal Large B Ce... More >>ll Lymphoma Less << Phase 2 Completed - Italy ... More >> S.C. Ematologia A.O. SS. Antonio e Biagio e C. Arrigo Alessandria, AL, Italy, 15121 Unità funzionale di Ematologia A.O.U. Careggi Firenze, FI, Italy, 50134 Dip. Oncologia, Ematologia e Patologie dell'apparato respiratorio A.O.U. Policlinico di Modena Modena, MO, Italy, 41100 Divisione di Ematologia Azienda Ospedaliera "Bianchi Melacrino Morelli" Reggio Calabria, RC, Italy, 89125 S. C. Ematologia IRCCS Azienda Ospedaliera Arcispedale "S.Maria Nuova" Reggio Emilia, RE, Italy, 4210 S.C.D.O. Ematologia 2 A.O. Città della Salute e della Scienza Torino, TO, Italy, 1012 Istituto di Ematologia L. & A. Seragnoli Bologna, Italy, 40138 Ematologia Ospedale Businco Cagliari, Italy, 09121 Dipartimento di Biotecnologie Cellulari ed Ematologia Università "La Sapienza" Roma, Italy, 0016 Less <<
NCT02423291 - Completed - -
NCT01596218 Graft vs. Host Disease Phase 1 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States United States, Ohio Ohio State University Columbus, Ohio, United States Less <<
NCT01396070 Non-Hodgkin Lymphoma (NHL)|Cut... More >>aneous Lymphoma|Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides|Sezary Syndrome Less << PHASE2 COMPLETED 2025-05-16 Stanford University School of ... More >>Medicine, Stanford, California, 94305, United States Less <<
NCT03245736 Ovary Cancer ... More >>Cervix Cancer Endometrium Cancer Bladder Cancer Prostate Cancer Esophagus Cancer Lung Cancer, Nonsmall Cell Squamous Cell Carcinoma of the Head and Neck Less << Phase 2 Recruiting January 1, 2022 United States, Florida ... More >> Brian Slomovitz Recruiting Miami, Florida, United States, 33136 Contact: Brian Slomovitz, Dr          United Kingdom Johann de Bono Recruiting Chelsea, United Kingdom, SM2 5PT Contact: Johann de Bono, Professor          Beatson Cancer Centre Recruiting Glasgow, United Kingdom Principal Investigator: Robert Jones, Dr          Fiona Thistlethwaite Recruiting Manchester, United Kingdom, M20 4BX Contact: Fiona Thistlethwaite, Dr Less <<
NCT02227433 Hodgkin Lymphoma Phase 2 Active, not recruiting April 2019 Italy ... More >> Irccs Centro Di Riferimento Oncologico Di Aviano (Pn) Aviano, Italia, Italy, 33081 Policlinico S.Orsola Malpighi Bologna, Italy Irccs Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli Napoli, Italy Università La Sapienza Rome, Italy, 00161 Less <<
NCT01421667 Lymphoma, B-Cell ... More >> Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoma, T-Cell Less << Phase 2 Completed - -
NCT01851200 Germ Cell Cancer Phase 2 Completed - Italy ... More >> Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Mi, Italy, 20133 Less <<
NCT01807598 Aggressive Systemic Mastocytos... More >>is|Mast Cell Leukemia|Systemic Mastocytosis Less << PHASE2 COMPLETED 2025-09-17 Stanford University, School of... More >> Medicine, Stanford, California, 94305, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01421667 - Completed - -
NCT01508312 Hodgkin's Lymphoma Phase 2 Active, not recruiting September 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01671813 Lymphoma Not Applicable Withdrawn(Terminated by pharma... More >>ceutical sponsor - no accrual) Less << - -
NCT02939014 Hodgkin Disease ... More >> Lymphoma, Large-Cell, Anaplastic Less << Phase 2 Active, not recruiting December 1, 2019 China, Beijing ... More >> Beijing, Beijing, China China, Guangdong Guangzhou, Guangdong, China China, Jiangsu Nanjing, Jiangsu, China China, Jilin Changchun, Jilin, China China, Shanghai Shanghai, Shanghai, China China, Tianjin Tianjin, Tianjin, China China, Zhejiang Hangzhou, Zhejiang, China Less <<
NCT02588651 T-cell Lymphoma|Angioimmunobla... More >>stic T-cell Lymphoma|Hepato-splenic T-cell Lymphoma|Adult T-cell Leukemia/Lymphoma|Enteropathy Associated T-cell Lymphoma|NK T-cell Lymphoma Less << PHASE2 ACTIVE_NOT_RECRUITING 2027-12-15 Wayne State University, Karman... More >>os Cancer Institute, Detroit, Michigan, 48201, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, 44195, United States Less <<
NCT02280785 Non-Hodgkin Lymphoma PHASE2 COMPLETED 2025-09-18 National Cancer Center, Goyang... More >>-si, Gyeonggi-do, 410-769, Korea, Republic of|Yonsei Severance Hospital, Seoul, 120-752, Korea, Republic of|Asan Medical Center, Seoul, 138-736, Korea, Republic of|Korean Cancer Center Hospital, Seoul, 139-706, Korea, Republic of Less <<
NCT01841021 Peripheral T-Cell Lymphoma TERMINATED 2025-06-16 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT01909934 Lymphoma PHASE4 COMPLETED 2024-08-29 ZNA Stuivenberg, Antwerpen, 20... More >>60, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, 1200, Belgium|Universitair Ziekenhuis Gent, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|Clinical Hospital Centre Rijeka, Rijeka, 51000, Croatia|Clinical Hospital Centre Zagreb, Zagreb, 10000, Croatia|Clinical Hospital Dubrava, Zagreb, 10000, Croatia|Fakultni nemocnice Brno, Brno, 625 00, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, 100 34, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Semmelweis Egyetem, Budapest, 1083, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Pecsi Tudomanyegyetem, Pecs, 7624, Hungary|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-952, Poland|Malopolskie Centrum Medyczne s.c., Krakow, 30-510, Poland|SPZOZ MSW zWarminsko-MazurskimCen.Onko.wOlsztynie, Olsztyn, 10-228, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, 02-781, Poland|Hospital de Braga, Braga, 4710-243, Portugal|Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisboa, 1649-035, Portugal|Centro Hospitalar do Porto, E.P.E. - Hospital de Santo Antonio, Porto, 4099-001, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto, 4200-072, Portugal|Policlinica de Diagnostic Rapid SA, Brasov, 500152, Romania|Spitalul Clinic Colentina, Bucuresti, 020125, Romania|Spitalul Clinic Coltea, Bucuresti, 030171, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Targu Mures, 540042, Romania|ICO lHospitalet Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Ankara University Medical Faculty, Ankara, 06340, Turkey|Pamukkale Uni. Med. Fac., Denizli, 20070, Turkey|Istanbul Bilim University Medical Fac., Istanbul, 34200, Turkey|Ege University Medical Faculty, Izmir, 35040, Turkey|Dokuz Eylul University Faculty of Medicine, Izmir, 35340, Turkey|Erciyes University Medical Faculty, Kayseri, 38039, Turkey|Royal Cornwall Hospital, Truro, Cornwall, TR1 3LJ, United Kingdom|The Christie, Manchester, Greater Manchester, M20 4BX, United Kingdom|Birmingham Heartlands Hospital, Birmingham, West Midlands, B9 5SS, United Kingdom Less <<
NCT01393717 Recurrent Hodgkin Lymphoma ... More >> Refractory Hodgkin Lymphoma Less << Phase 2 Completed - United States, California ... More >> City of Hope Medical Center Duarte, California, United States, 91010 United States, New York Weill Medical College, Cornell University New York, New York, United States, 10065 Less <<
NCT03587844 Mycosis Fungoides ... More >> Lymphomatoid Papulosis Less << Phase 2 Recruiting July 2020 United States, California ... More >> Stanford University Medical Center Not yet recruiting Stanford, California, United States, 94305-5408 Contact: Youn Kim, MD    650-498-6000       United States, New Jersey Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Alison Moskowitz, MD    212-639-4839       Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Alison Moskowitz, MD    212-639-4839       United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Alison Moskowitz, MD    212-639-4839       Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Alison Moskowitz, MD    212-639-4839       Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Alison Moskowitz, MD    212-639-4839       Contact: Steven Horwitz, MD    212-639-3045       Principal Investigator: Alison Moskowitz, MD          Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Alison Moskowtiz, MD    212-639-4839 Less <<
NCT01393717 - Completed - -
NCT01841021 Peripheral T-Cell Lymphoma TERMINATED 2025-06-16 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT02780011 CD30-positive Lymphoma ... More >> CD30-positive Solid Tumor Less << Phase 1 Withdrawn(lack of funding) September 2018 United States, Texas ... More >> Houston Methodist Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03205891 Malignant Neoplasms Stated as ... More >>Primary Lymphoid Haematopoietic Classical Hodgkin Lymphoma Anaplastic Large Cell Lymphoma CD30+ Peripheral T-cell Lymphoma Less << Phase 1 Withdrawn(Change in treatment ... More >>priorities for these disease types as well as staffing concerns.) Less << March 2021 -
NCT01492088 Relapsed or Refractory Hodgkin... More >> Lymphoma|Relapsed or Refractory Anaplastic Large-cell Lymphoma Less << PHASE1|PHASE2 COMPLETED 2018-04-12 Aurora, Colorado, United State... More >>s|Kansas City, Missouri, United States|New York, New York, United States|Houston, Texas, United States|Bordeaux Cedex, France|Lyon, France|Paris Cedex 12, France|Berlin, Germany|Frankfurt, Germany|Giessen, Germany|Halle, Germany|Munster, Germany|Padova, Italy|Roma, Italy|Mexico Df, Mexico|Rotterdam, Netherlands|Barcelona, Spain|London, United Kingdom Less <<
NCT01990534 - Active, not recruiting - -
NCT01990534 Hodgkin Lymphoma Phase 4 Active, not recruiting March 2020 Czech Republic ... More >> Praha, Prague, Czech Republic Brno, Czech Republic Germany Heidelberg, Baden Wuerttemberg, Germany Koeln, Germany Malaysia Georgetown, Penang, Malaysia Ampang, Selangor, Malaysia Kuala Lumpur, Malaysia Poland Gdansk, Poland Krakow, Poland Warszawa, Poland Spain Pamplona, Navarra, Spain Madrid, Spain Thailand Bangkoknoi, Bangkok, Thailand Patumwan, Bangkok, Thailand Ratchathewi, Bangkok, Thailand Turkey Izmir, Bornova, Turkey Ankara, Turkey Izmir, Turkey Less <<
NCT03007030 Lung Diseases Due to External ... More >>Agents Mesothelioma Less << Phase 2 Recruiting April 2022 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       astsao@mdanderson.org Less <<
NCT02567851 Hodgkin Disease Phase 2 Completed - United Kingdom ... More >> Queen Elizabeth Hospital Birmingham, United Kingdom University Hospital of Wales Cardiff, United Kingdom Beatson West of Scotland Cancer Center Glasgow, United Kingdom St James University Hospital Leeds, United Kingdom University Hospital Leicester, United Kingdom Royal Liverpool Hospital Liverpool, United Kingdom Guys Hospital London, United Kingdom The Christie Hospital Manchester, United Kingdom, M20 4BX The Freeman Hospital Newcastle, United Kingdom Norfolk and Norwich Hospital Norwich, United Kingdom The Churchill Hospital Oxford, United Kingdom Southampton General Hospital Southampton, United Kingdom Less <<
NCT02713828 Squamous Cell Carcinoma of the... More >> Lung Less << Phase 1 Phase 2 Terminated(Company discontinue... More >>d further development of study drug for this indication) Less << - United States, Florida ... More >> University of Miami Hospital Miami, Florida, United States, 33136 United States, Georgia Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Louisiana Ochsner Medical Center New Orleans, Louisiana, United States, 70121 United States, Nebraska Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68106 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York Stony Brook University Stony Brook, New York, United States, 11794-9446 United States, Pennsylvania Penn State Hershey Cancer Institute Hershey, Pennsylvania, United States, 17033 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 United States, Wisconsin Gundersen Health System La Crosse, Wisconsin, United States, 54601 Less <<
NCT01492088 Relapsed or Refractory Hodgkin... More >> Lymphoma|Relapsed or Refractory Anaplastic Large-cell Lymphoma Less << PHASE1|PHASE2 COMPLETED 2018-04-12 Aurora, Colorado, United State... More >>s|Kansas City, Missouri, United States|New York, New York, United States|Houston, Texas, United States|Bordeaux Cedex, France|Lyon, France|Paris Cedex 12, France|Berlin, Germany|Frankfurt, Germany|Giessen, Germany|Halle, Germany|Munster, Germany|Padova, Italy|Roma, Italy|Mexico Df, Mexico|Rotterdam, Netherlands|Barcelona, Spain|London, United Kingdom Less <<
NCT02388490 Relapsed or Refractory EBV-and... More >> CD30-positive Lymphomas Less << Phase 2 Active, not recruiting September 2018 Korea, Republic of ... More >> Seoul National University Bundang Hospital Seongnam, Korea, Republic of Seoul National Unversity Hospital Seoul, Korea, Republic of SMG-SNU Boramae Medical Center Seoul, Korea, Republic of Less <<
NCT03070990 Metastatic Urothelial Cancer Phase 1 Active, not recruiting March 2019 Japan ... More >> Site JP00003 Tsukuba, Ibaraki, Japan Site JP00005 Sendai, Miyagi, Japan Site JP00008 Suita, Osaka, Japan Site JP00004 Chuo, Tokyo, Japan Site JP00007 Koto, Tokyo, Japan Site JP00006 Fukuoka, Japan Site JP00001 Niigata, Japan Site JP00002 Okayama, Japan Less <<
NCT03302728 Lymphoma, T-Cell, Cutaneous ... More >> Lymphoma, T-Cell, Peripheral Hodgkin Lymphoma Less << Phase 1 Not yet recruiting August 15, 2021 Australia, Victoria ... More >> Peter MacCallum Cancer Centre Not yet recruiting Melbourne, Victoria, Australia, 3000 Contact: Maria Farrell, Ms Less <<
NCT01940796 Graft-vs-Host Disease ... More >> GVHD Less << Phase 1 Terminated(Toxicity) - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02215 Less <<
NCT02164006 Hodgkin's Lymphoma Phase 1 Active, not recruiting February 2019 United States, California ... More >> TG Therapeutics Investigational Trial Site Duarte, California, United States, 91010 TG Therapeutics Investigational Trial Site San Diego, California, United States, 92093 United States, Florida TG Therapeutics Investigational Trial Site Sarasota, Florida, United States, 34232 United States, Michigan TG Therapeutics Investigational Trial Site Detroit, Michigan, United States, 48201 Less <<
NCT05357794 Mycosis Fungoides PHASE2 RECRUITING 2026-01-30 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<
NCT05442554 T-Cell Lymphoma PHASE4 COMPLETED 2024-08-09 Peking University First Hospit... More >>al, Beijing, Beijing, 100034, China|Peking University Third Hospital, Beijing, Beijing, 100191, China|Huashan Hospital, Fudan University, Shanghai, Shanghai, 200040, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China Less <<
NCT06186986 Diffuse Large B-cell-lymphoma PHASE3 NOT_YET_RECRUITING 2025-01-26 -
NCT05243693 Relapsed/Refractory Classical ... More >>Hodgkin Lymphoma Less << PHASE2 RECRUITING 2026-03-31 Hyeon-Seok Eom, Goyang, Gyeong... More >>gi-do, 10408, Korea, Republic of Less <<
NCT05149768 Diffuse Cutaneous Systemic Scl... More >>erosis Less << PHASE2 RECRUITING 2026-07-01 Rheumatology Clinic, St. Josep... More >>h's Health Care, London, Ontario, N6A 4V2, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.39mL

0.28mL

0.14mL

6.96mL

1.39mL

0.70mL

13.93mL

2.79mL

1.39mL

References

 

Historical Records

Categories